论文部分内容阅读
目的:探讨盐酸氨溴索口服液联合孟鲁司特钠咀嚼片对小儿哮喘血清MMP-9和TIMP-1水平及肺功能的影响。方法:收集我院就诊或住院治疗的120例小儿哮喘患者,随机分为实验组和对照组,每组60例。两组患者入院后均给予相应的对症治疗,对照组患者在此基础上给予孟鲁司特钠咀嚼片治疗,实验组患者在对照组的基础上给予盐酸氨溴索口服液治疗。治疗结束后对患者血清MMP-9、TIMP-1,患者肺功能水平以及临床疗效进行检测并比较。结果:与治疗前相比,治疗后两组患者血清MMP-9、TIMP-1水平下降(P<0.05),FEV1、FVC、PEF水平升高(P<0.05);与对照组相比,实验组患者血清MMP-9、TIMP-1水平较低(P<0.05),FEV1、FVC、PEF水平较高(P<0.05),治疗总有效率较高(P<0.05)。结论:盐酸氨溴索口服液联合孟鲁司特钠咀嚼片能够降低小儿哮喘患者血清MMP-9、TIMP-1水平,改善肺功能,临床疗效较好,对临床有指导意义。
Objective: To investigate the effect of ambroxol hydrochloride oral liquid combined with montelukast sodium chewable tablets on serum MMP-9, TIMP-1 and pulmonary function in children with asthma. Methods: A total of 120 pediatric asthma patients who were treated or hospitalized in our hospital were randomly divided into experimental group and control group, with 60 cases in each group. Both groups were given symptomatic treatment after admission. Patients in the control group were given montelukast sodium chewable tablets on this basis. Patients in the experimental group were treated with ambroxol hydrochloride oral liquid on the basis of the control group. Serum MMP-9, TIMP-1, pulmonary function and clinical efficacy were measured and compared after treatment. Results: Compared with those before treatment, the levels of serum MMP-9 and TIMP-1 decreased (P <0.05) and the levels of FEV1, FVC and PEF increased (P <0.05) The serum levels of MMP-9, TIMP-1 were lower (P <0.05), FEV1, FVC and PEF were higher (P <0.05), and the total effective rate was higher (P <0.05). Conclusion: Ambroxol hydrochloride oral liquid combined with montelukast sodium chewable tablets can reduce serum levels of MMP-9 and TIMP-1 in children with asthma and improve pulmonary function. The clinical effect is good and has clinical significance.